Pharmaceutical company's cenvat credit upheld as research activities integral to manufacturing process under Rule 3

CESTAT Chandigarh dismissed Revenue's appeal challenging cenvat credit availed by pharmaceutical company. Revenue alleged respondent only conducted research and development activities, not manufacturing, making cenvat credit impermissible under Rule 3 of Cenvat Credit Rules, 2004. CESTAT held Revenue's case relied solely on unproduced statement of respondent's scientist, denying proper opportunity to defend. Tribunal found pharmaceutical research integral to drug manufacturing process, and respondent was registered for service tax on R&D activities, entitling cenvat credit. Commissioner correctly concluded entire demand was time-barred. Appeal dismissed upholding respondent's entitlement to cenvat credit.

---

---

Issues Involved:
1. Entitlement to CENVAT credit for non-manufacturing activities.
2. Validity of the extended period for recovery of CENVAT credit.
3. Adequacy of evidence provided by the Revenue.

Summary:

Entitlement to CENVAT Credit:
The Respondent, M/s Ind-Swift Laboratories, registered for central excise and availed CENVAT credit on capital goods, inputs, and input services. The Revenue alleged that the Respondent was not entitled to CENVAT credit as they were engaged solely in Research and Development (R&D) activities and not in manufacturing. The Ld. Commissioner vacated the show cause notice, stating that the Respondent was entitled to CENVAT credit even for R&D activities as they were registered under Service Tax for Scientific and Technical Consultancy Services and were regularly paying service tax. The Tribunal upheld this finding, noting that the Respondent's machinery was capable of manufacturing pharmaceutical products and that significant research and testing are inherent to pharmaceutical manufacturing.

Validity of the Extended Period:
The Revenue invoked the extended period for recovery of CENVAT credit, alleging suppression of facts. The Ld. Commissioner found that the demand was barred by limitation, as the Respondent had filed statutory returns and maintained records as required by law. The Tribunal agreed, citing the Supreme Court's ruling that extended periods require evidence of fraud, collusion, or wilful misstatement with intent to evade tax. The Tribunal noted that the Revenue failed to provide such evidence and that the Respondent had transparently declared the availing and utilization of CENVAT credit in their returns.

Adequacy of Evidence:
The Revenue's case relied on the statement of a Senior Scientist from the Respondent, claiming the unit was designed only for R&D. However, this statement was not provided to the Respondent, nor was it substantiated by technical expert reports. The Tribunal found that the Revenue did not provide sufficient evidence to prove that the Respondent's machinery was incapable of manufacturing activities. The Tribunal upheld the Ld. Commissioner's reliance on a Chartered Engineer's certificate confirming the machinery's capability for manufacturing.

Conclusion:
The Tribunal dismissed the Revenue's appeal, affirming the Ld. Commissioner's order that the Respondent was entitled to CENVAT credit and that the demand was barred by limitation. The Tribunal emphasized the lack of evidence for the Revenue's claims and the necessity for transparency and due process in tax recovery actions.

---